NeurAxis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRXS research report →
Range $8 – $8
Price Chart
About the company
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18.
- CEO
- Brian Carrico
- IPO
- 2023
- Employees
- 24
- HQ
- Carmel, IN, US
Get TickerSpark's AI analysis on NRXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $59.90M
- P/E
- -4.02
- Fwd P/E
- 422.00
- PEG
- 0.23
- P/S
- 9.17
- P/B
- 15.13
- EV/EBITDA
- -4.67
- Div Yield
- 0.00%
- Gross Margin
- 86.16%
- Op Margin
- -186.16%
- Net Margin
- -188.18%
- ROE
- -252.10%
- ROIC
- -305.99%
Latest fiscal year · YoY change
- Revenue
- $3.57M+32.9%
- Gross Profit
- $3.01M+29.4%
- Op Income
- $-7,829,908
- Net Income
- $-7,800,555+5.4%
- EPS
- $-0.95+22.1%
- OCF Growth
- -5.5%
- FCF Growth
- -5.5%
- 52W High
- $9.33
- 52W Low
- $2.50
- 50D MA
- $6.76
- 200D MA
- $6.75
- Beta
- 1.38
- RSI (14)
- 26
- Avg Volume
- 148.58K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NeurAxis said Q3 revenue rose 150% year over year as payer coverage expanded, reimbursement mix improved, and management began scaling the commercial team.· November 9, 2026
- Q3 revenue was $2 million, up 150% from $811,000 last year; 9-month revenue rose 114% to $5.6 million.
- Gross margin expanded to 86.6% in Q3 from 83.3% a year ago, helped by a shift from financial assistance to reimbursed treatments.
- Coverage expanded to about 147 million covered lives after two large payer wins in the last 45 days, with management expecting more impact in Q4 and 2027.
- Year-to-date prior authorization approval rate improved from 12% in 2025 to 32% at 9/30 and just over 38% by 10/30.
- Management is adding sales, market access, and clinical personnel, including at least 5 additional full-time sales territories, which should lift costs in the short term.
Revenue in Q3 2026 was $2 million, up 150% year over year from $811,000. For the first nine months of 2026, revenue was $5.6 million, up 114% from $2.6 million. Gross margin was 86.6% in Q3 2026 versus 83.3% in Q3 2025, and 86.3% for the nine months versus 83.8% last year. Average selling price rose to $1,045 per device in Q3 from $775, and to $1,018 year to date from $773. Operating loss was $6.6 million in Q3, and net loss was $6.5 million; on an adjusted basis excluding one-time stock comp charges, operating loss would have been $2.3 million and net loss $2.2 million. Cash on hand was $4.5 million at September 30, and free cash outflow was $2.3 million in Q3 and $4.5 million year to date. Management did not issue formal numeric revenue guidance, but said the two recent payer additions should contribute in Q4 with a more meaningful impact in 2027, and that the new sales and market access investments will increase near-term expenses and cash burn.
Brian Carrico framed the quarter as a turning point, emphasizing that insurance coverage is the key driver of scalable growth. He highlighted the addition of two large payers, coverage reaching approximately 147 million lives, and the company’s push to translate policy wins into actual reimbursement and utilization. His tone was constructive but measured: he repeatedly noted that policy wins take time to flow through to revenue and that the company is still working through implementation issues, especially around prior authorizations and Medicaid fee schedules.
Tim Henrichs focused on operating momentum and margin improvement, saying Q3 was the ninth straight quarter of double-digit revenue growth and the second consecutive quarter above 100% growth. He tied the improvement to the Category I CPT code, expanded payer coverage, and the shift to higher-margin reimbursed treatments, which lifted gross margin to 86.6%. He also flagged increased spending: operating expenses were $8.3 million in Q3, cash was $4.5 million at quarter-end, and the company raised nearly $1.7 million via the ATM after quarter end. He said burn will increase in the short term as NeurAxis invests in sales, marketing, clinical, and R&D capabilities, but reiterated confidence in future cash flow breakeven.
Analysts focused on how quickly the recent Cigna and Aetna wins will translate into revenue, and management said one payer is already contributing while the other has been delayed by a prior-authorization miscommunication that should be fixed soon. Brian said the effect should start showing in Q4 and become more meaningful in 2027, especially if the issue is resolved. Questions also centered on salesforce sizing and Medicaid adoption; management said direct sales should reach 10 or 11 reps by year-end, with broader commercial support bringing the total to roughly 12 to 16 depending on how roles are counted. On Medicaid, Brian said NeurAxis likely has only 2 or 3 state Medicaid policies today, but 27 states have the CPT code on the fee schedule, and he thinks the company could reach about 90% of states/territories by spring 2027, possibly as early as Q1.
The call showed clear operating leverage from reimbursement progress: revenue growth, higher ASPs, and gross margin expansion all moved in the right direction at the same time. Management believes the recent payer wins and expanded commercial footprint should support stronger utilization in covered markets, with more upside as implementation issues get resolved and additional payers come on board. The VA channel and adult study also give the company longer-term optionality beyond the pediatric core.
The main risk is that coverage wins do not convert into revenue immediately; management acknowledged implementation delays, incomplete Medicaid fee schedules, and prior-authorization friction at a major payer. The company is also increasing SG&A and cash burn as it hires sales, marketing, market access, and R&D staff, while cash at quarter-end was only $4.5 million. Management did not provide formal financial guidance, and timing for new payer policies remains difficult to predict.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 68.1%
- Shares Outstanding
- 14.19M
- Float Shares
- 9.66M
of shares held by institutions
32 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rosalind Advisors, Inc. | 548.12K | ▲ 40.07K |
| Aigh Capital Management LLC | 540.29K | ▲ 20.35K |
| Vanguard Capital Management LLC | 341.95K | ▲ 6.16K |
| Money Concepts Capital Corp | 235.67K | ▲ 7.64K |
| Renaissance Technologies LLC | 156.30K | ▼ 13.10K |
| Vanguard Group Inc | 145.56K | ▲ 73.93K |
| Geode Capital Management, LLC | 91.00K | ▼ 5.36K |
| Parsons Capital Management Inc/Ri | 90.81K | ▼ 27.00K |
| Eddie Patel Inc | 79.54K | ▲ 19.78K |
| Blackrock, Inc. | 60.13K | ▲ 1.47K |
| Vanguard Fiduciary Trust Co | 51.00K | ▼ 8.70K |
| State Street Corp | 47.74K | ▲ 3.50K |
Held by 24 ETFs
Biggest fund positions in NRXS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 26 | Carrico Brian Allen | buy | 268 |
| Oct 8, 26 | Carrico Thomas Joeseph | buy | 328 |
| Oct 8, 26 | Henrichs Timothy Robert | buy | 1,937 |
| Sep 28, 26 | Blanchard Craig Thomas | other | 0 |
| Aug 24, 26 | Carrico Thomas Joeseph | other | 306,236 |
| Aug 24, 26 | Carrico Thomas Joeseph | other | 193,678 |
| Aug 24, 26 | Carrico Thomas Joeseph | other | 306,236 |
| Aug 24, 26 | Carrico Thomas Joeseph | other | 306,236 |
| Aug 24, 26 | Miranda Adrian | other | 337,204 |
| Aug 24, 26 | Miranda Adrian | other | 199,106 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRXS coverage
Recent articles, reports, and earnings notes.
No research on NRXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRXS report →NeurAxis (NASDAQ:NRXS) and Anteris Technologies Global (NASDAQ:AVR) Head-To-Head Review
defenseworld.net · Nov 14
NeurAxis, Inc. (NRXS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth
globenewswire.com · Nov 9
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
globenewswire.com · Oct 27
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
globenewswire.com · Oct 15
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)
defenseworld.net · Oct 12
Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS)
defenseworld.net · Oct 5
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
globenewswire.com · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.